129 related articles for article (PubMed ID: 38224873)
1. TERT promoter mutations in atypical melanocytic lesions: A series of seven cases with adverse melanoma-specific outcome.
Huber R; Lee J; Borretta L; Tessier-Cloutier B; Lum A; Yip S; Horst BA
Hum Pathol; 2024 Feb; 144():34-39. PubMed ID: 38224873
[TBL] [Abstract][Full Text] [Related]
2. Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis.
Thomas NE; Edmiston SN; Tsai YS; Parker JS; Googe PB; Busam KJ; Scott GA; Zedek DC; Parrish EA; Hao H; Slater NA; Pearlstein MV; Frank JS; Kuan PF; Ollila DW; Conway K
Am J Dermatopathol; 2019 Apr; 41(4):264-272. PubMed ID: 30211730
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Koopmans AE; Ober K; Dubbink HJ; Paridaens D; Naus NC; Belunek S; Krist B; Post E; Zwarthoff EC; de Klein A; Verdijk RM;
Invest Ophthalmol Vis Sci; 2014 Aug; 55(9):6024-30. PubMed ID: 25159205
[TBL] [Abstract][Full Text] [Related]
4. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis.
Motaparthi K; Kim J; Andea AA; Missall TA; Novoa RA; Vidal CI; Fung MA; Emanuel PO
J Cutan Pathol; 2020 Aug; 47(8):710-719. PubMed ID: 32202662
[TBL] [Abstract][Full Text] [Related]
5. The role of TERT promoter mutations in differentiating recurrent nevi from recurrent melanomas: A retrospective, case-control study.
Walton KE; Garfield EM; Zhang B; Quan VL; Shi K; Mohan LS; Haugh AM; VandenBoom T; Yazdan P; Isales MC; Panah E; Gerami P
J Am Acad Dermatol; 2019 Mar; 80(3):685-693. PubMed ID: 30287318
[TBL] [Abstract][Full Text] [Related]
6. PRAME Immunohistochemical Expression and TERT Promoter Mutational Analysis as Ancillary Diagnostic Tools for Differentiating Proliferative Nodules From Melanoma Arising in Congenital Nevi.
Boutko A; Hagstrom M; Lampley N; Roth A; Olivares S; Dhillon S; Fumero-Velázquez M; Benton S; Zhao J; Zhang B; Dittmann D; Asadbeigi S; Busam KJ; Gerami P
Am J Dermatopathol; 2023 Jul; 45(7):437-447. PubMed ID: 37338065
[TBL] [Abstract][Full Text] [Related]
7. TERT Promoter Mutational Analysis as an Ancillary Diagnostic Tool for Diagnostically Challenging Melanocytic Neoplasms.
Boutko A; Asadbeigi S; Roth A; Lampley N; Olivares S; Dittmann D; Dittmann D; Jennings L; Gerami P
Am J Dermatopathol; 2023 May; 45(5):289-299. PubMed ID: 36898007
[TBL] [Abstract][Full Text] [Related]
8. Atypical melanocytic nevi of the genital type with a discussion of reciprocal parenchymal-stromal interactions in the biology of neoplasia.
Clark WH; Hood AF; Tucker MA; Jampel RM
Hum Pathol; 1998 Jan; 29(1 Suppl 1):S1-24. PubMed ID: 9445124
[TBL] [Abstract][Full Text] [Related]
9. Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors.
Zaremba A; Jansen P; Murali R; Mayakonda A; Riedel A; Philip M; Rose C; Schaller J; Müller H; Kutzner H; Möller I; Stadtler N; Kretz J; Sucker A; Bankfalvi A; Livingstone E; Zimmer L; Horn S; Paschen A; Plass C; Schadendorf D; Hadaschik E; Lutsik P; Griewank K
Int J Cancer; 2022 Nov; 151(9):1542-1554. PubMed ID: 35737508
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of atypical deep penetrating nevus progressing to melanoma.
Isales MC; Khan AU; Zhang B; Compres EV; Kim D; Tan TL; Beaubier N; Gerami P
J Cutan Pathol; 2020 Dec; 47(12):1150-1154. PubMed ID: 32526042
[TBL] [Abstract][Full Text] [Related]
11. Melanocytic proliferations associated with lichen sclerosus.
Carlson JA; Mu XC; Slominski A; Weismann K; Crowson AN; Malfetano J; Prieto VG; Mihm MC
Arch Dermatol; 2002 Jan; 138(1):77-87. PubMed ID: 11790170
[TBL] [Abstract][Full Text] [Related]
12. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
Bahmad HF; Oh KS; Alexis J
J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
[TBL] [Abstract][Full Text] [Related]
13. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
[TBL] [Abstract][Full Text] [Related]
14. Telomerase Expression in a Series of Melanocytic Neoplasms.
de Unamuno Bustos B; Sahuquillo Torralba A; Moles Poveda P; Pérez Simó G; Simarro Farinos J; Llavador Ros M; Palanca Suela S; Botella Estrada R
Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):212-219. PubMed ID: 30591199
[TBL] [Abstract][Full Text] [Related]
15. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
16. Black and Brown Oro-facial Mucocutaneous Neoplasms.
Natarajan E
Head Neck Pathol; 2019 Mar; 13(1):56-70. PubMed ID: 30693458
[TBL] [Abstract][Full Text] [Related]
17. Lack of distinct molecular profile of Primary Dermal Melanoma.
Shaigany S; Tessier-Cloutier B; Busam KJ; Horst BA
Hum Pathol; 2020 Dec; 106():32-38. PubMed ID: 32946880
[TBL] [Abstract][Full Text] [Related]
18. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi.
Kittler H; Pehamberger H; Wolff K; Binder M
J Am Acad Dermatol; 2000 Sep; 43(3):467-76. PubMed ID: 10954658
[TBL] [Abstract][Full Text] [Related]
19. Common acquired melanocytic nevi, melanocytic dysplasia and malignant melanoma. A morphometric study.
Santucci M; Urso C; Giannini A; Bondi R
Appl Pathol; 1989; 7(2):111-5. PubMed ID: 2730799
[TBL] [Abstract][Full Text] [Related]
20. Molecular Genomic Profiling of Melanocytic Nevi.
Colebatch AJ; Ferguson P; Newell F; Kazakoff SH; Witkowski T; Dobrovic A; Johansson PA; Saw RPM; Stretch JR; McArthur GA; Long GV; Thompson JF; Pearson JV; Mann GJ; Hayward NK; Waddell N; Scolyer RA; Wilmott JS
J Invest Dermatol; 2019 Aug; 139(8):1762-1768. PubMed ID: 30772300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]